Inflammatory Bowel Diseases

Skip Navigation LinksHome > March 2013 - Volume 19 - Issue 3 > Kinetics of Anti–Hepatitis B Surface Antigen Titers After He...
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e31827febe9
Original Clinical Articles

Kinetics of Anti–Hepatitis B Surface Antigen Titers After Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

Gisbert, Javier P. MD, PhD*,†; Villagrasa, Jose Ramón MD; Rodríguez-Nogueiras, Amelia (Nurse)*,†; Chaparro, María MD, PhD*,†

Collapse Box


Background: Clinically significant hepatitis B (HB) virus infection has been documented among immunocompromised patients who do not maintain anti–hepatitis surface antigen (anti-HBs) concentrations ≥10 IU/L after an adequate response to the vaccine. The aims of the study were to understand the kinetics of anti-HBs titers over time in patients with inflammatory bowel disease (IBD) who initially responded to vaccination and to identify factors predictive of losing protective anti-HBs titers.

Methods: Patients with IBD with a response (anti-HBs > 10 IU/L at 1–3 months) to HB virus vaccination were prospectively included. Anti-HBs titers were measured at 6 and 12 months. Anti-HBs titers were considered negative if they were <10 IU/L at any time during the follow-up. The kinetics of anti-HBs titers in the long term was estimated using Kaplan–Meier curves. Cox regression analysis was performed to identify the factors predictive of losing protective anti-HBs titers.

Results: The sample comprised 100 patients (mean age, 42 years; 68% Crohn’s disease; 49% on thiopurines; and 14% on anti–tumor necrosis factors during follow-up). The cumulative incidence of loss of anti-HBs titers was 2% after 6 months and 15% after 12 months. The incidence rate of loss of protective anti-HBs titers was 18% per patient-year. Baseline (after vaccination) anti-HBs titers were lower among patients whose titers became negative during the follow-up than among those who maintained them >10 IU/L (191 versus 515 IU/L; P < 0.001). Treatment with anti-TNFs was the only factor associated with a higher risk of loss of anti-HBs (hazard ratio = 3.1; 95% confidence interval = 1.1–8.8; P = 0.03).

Conclusions: A high proportion of patients with IBD with protective anti-HBs titers after vaccination lose them over time (18% per patient-year of follow-up). The risk of losing protective anti-HBs titers is 3-fold higher among patients on anti- tumor necrosis factors therapy.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.